Ototoxicity and drugs of ingredients of cisplatin - a phase IV clinical study of FDA data
Ototoxicity is found among people who take drugs with ingredients of cisplatin, especially for people who are female, 10-19 old , have been taking the drugs for < 1 month. This phase IV clinical study is created by eHealthMe based on reports of 74,835 people who have side effects when taking drugs with ingredients of cisplatin from the FDA, and is updated regularly.
Drug(s) considered in the study (i.e. both brand name and generic drugs): Cisplatin, Platinol, Platinol-aq.
With medical big data and AI algorithms, eHealthMe enables everyone to run phase IV clinical trial to detect adverse drug outcomes and monitor effectiveness. Our original studies have been referenced on 600+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Most recently, phase IV clinial trails for COVID 19 vaccines have been added, check here.
74,835 people reported to have side effects when taking drugs with ingredients of cisplatin.
Among them, 260 people (0.35%) have Ototoxicity
What is Ototoxicity?
Ototoxicity (damage to the ear) is found to be associated with 593 drugs and 325 conditions by eHealthMe.
Number of reports submitted per year:
Time on drugs with ingredients of cisplatin when people have Ototoxicity *:
- < 1 month: 56.25 %
- 1 - 6 months: 34.38 %
- 6 - 12 months: 6.25 %
- 1 - 2 years: 3.12 %
- 2 - 5 years: 0.0 %
- 5 - 10 years: 0.0 %
- 10+ years: 0.0 %
Gender of people who have Ototoxicity when taking drugs with ingredients of cisplatin *:
- female: 66.5 %
- male: 33.5 %
Age of people who have Ototoxicity when taking drugs with ingredients of cisplatin *:
- 0-1: 4.58 %
- 2-9: 9.8 %
- 10-19: 18.3 %
- 20-29: 11.11 %
- 30-39: 16.99 %
- 40-49: 11.76 %
- 50-59: 15.03 %
- 60+: 12.42 %
Conditions people have *:
- Gestational Trophoblastic Tumor: 37 people, 14.23%
- Medulloblastoma (a fast-growing, high-grade tumour that always begins in the cerebellum): 30 people, 11.54%
- Hepatoblastoma (liver cancer): 9 people, 3.46%
- Ovarian Cancer (cancer of ovary): 9 people, 3.46%
- Osteosarcoma (a cancerous (malignant) bone tumour): 8 people, 3.08%
- Cervix Carcinoma Stage Iii (cancer has spread to the lower third of the vagina, and/or to the pelvic wall): 7 people, 2.69%
- Pain: 7 people, 2.69%
- Germ Cell Cancer: 6 people, 2.31%
- Neoplasm Malignant (cancer tumour): 6 people, 2.31%
- Neuroblastoma (a cancer that forms in your nerve tissue): 6 people, 2.31%
Other drugs people take *:
- Etoposide: 43 people, 16.54%
- Methotrexate: 33 people, 12.69%
- Dactinomycin: 28 people, 10.77%
- Gemcitabine: 13 people, 5.00%
- Cosmegen: 12 people, 4.62%
- Carboplatin: 11 people, 4.23%
- Paclitaxel: 11 people, 4.23%
- Alimta: 9 people, 3.46%
- Taxotere: 8 people, 3.08%
- Cyclophosphamide: 8 people, 3.08%
Other side effects people have besides Ototoxicity *:
- Tinnitus (a ringing in the ears): 26 people, 10.00%
- Neuropathy Peripheral (surface nerve damage): 22 people, 8.46%
- Thrombocytopenia (decrease of platelets in blood): 22 people, 8.46%
- Nausea (feeling of having an urge to vomit): 20 people, 7.69%
- Nephropathy Toxic (damage to kidney due to toxins): 20 people, 7.69%
- Bone Marrow Failure: 17 people, 6.54%
- Febrile Neutropenia (fever with reduced white blood cells): 15 people, 5.77%
- Nausea And Vomiting: 15 people, 5.77%
- Neurotoxicity (when the exposure to natural or artificial toxic substances, which are called neurotoxins, alters the normal activity of the nervous system): 14 people, 5.38%
- Agranulocytosis (a deficiency of granulocytes in the blood, causing increased vulnerability to infection): 13 people, 5.00%
* Approximation only. Some reports may have incomplete information.
How to use the study?
You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.
Related publications that referenced our studies
- Schlumbrecht MP, Hehr K, "Cisplatin-induced bradycardia and the importance of the QT interval", Journal of Oncology Pharmacy Practice, 2015 Jan .
Drugs with ingredients of cisplatin, their effectiveness, alternatives and more:
How the study uses the data?
The study uses data from the FDA. It is based on cisplatin. All drugs that have the same active ingredients (e.g. brand name and generic drugs) are considered. Dosage of drugs is not considered in the study.
Who is eHealthMe?
With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).
WARNING, DISCLAIMER, USE FOR PUBLICATION
WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.
DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.
If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.
Recent studies on eHealthMe:
- How effective is Budesonide for Crohn'S Disease? - 4 seconds ago
- Zometa and Disturbance In Attention - 9 seconds ago
- Irbesartan and Performance Status Decreased - 12 seconds ago
- How effective is Vitamin B12 for Stress And Anxiety? - 26 seconds ago
- Pulmicort and Hypophagia - 30 seconds ago